ProQR Therapeutics N.V. | Micro-cap | Healthcare
$2.39
-1.65%
| ProQR Therapeutics Stock Comparison:
ProQR Therapeutics vs VertexProQR Therapeutics vs RegeneronProQR Therapeutics vs Bright MindsProQR Therapeutics vs Atea PharmaceuticalsProQR Therapeutics vs Third Harmonic BioProQR Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 4.5M
Operating Income -14.3M -320.91%
Net Income -14.2M -319.07%
EPS (Diluted) $-0.12

Balance Sheet Metrics

Total Assets 160.4M
Total Liabilities 82.3M
Shareholders Equity 78.1M
Debt to Equity 1.05

Cash Flow Metrics

Operating Cash Flow -14.1M
Free Cash Flow -13.4M

Revenue & Profitability Trend

ProQR Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i22.0M6.5M3.6M1.3M0
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i42.4M25.1M50.9M42.2M38.1M
Selling, General & Administrative i15.9M16.2M18.7M17.4M13.7M
Other Operating Expenses i-746.4K-80.0K-765.0K-1.0M-9.5M
Total Operating Expenses i57.6M41.3M68.8M58.5M42.4M
Operating Income i-35.5M-34.8M-65.2M-57.2M-42.4M
Operating Margin % i-161.2%-534.1%-1,813.0%-4,285.4%0.0%
Non-Operating Items
Interest Income i3.8M2.6M106.0K5.0K313.0K
Interest Expense i1.3M1.2M5.1M3.4M2.0M
Other Non-Operating Income394.2K5.6M6.1M-72.0K-2.4M
Pre-tax Income i-32.6M-27.8M-64.1M-60.7M-46.5M
Income Tax i-229.7K-78.0K96.0K117.0K124.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-32.4M-27.7M-64.2M-60.8M-46.6M
Net Margin % i-146.9%-425.8%-1,786.4%-4,554.2%0.0%
Key Metrics
EBITDA i-28.1M-28.7M-59.8M-57.0M-40.1M
EPS (Basic) i$-0.32$-0.35$-0.90$-0.96$-0.93
EPS (Diluted) i$-0.32$-0.35$-0.90$-0.96$-0.93
Basic Shares Outstanding i10039664274294373691335036193578548308196
Diluted Shares Outstanding i10039664274294373691335036193578548308196

Income Statement Trend

ProQR Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i174.2M118.9M94.8M187.5M75.8M
Short-term Investments i-----
Accounts Receivable i-----
Inventory i-----
Other Current Assets-----
Total Current Assets i179.4M121.0M154.5M191.5M80.0M
Non-Current Assets
Property, Plant & Equipment i37.4M32.1M29.1M27.8M26.6M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets-----
Total Non-Current Assets i16.5M16.9M16.9M18.1M18.7M
Total Assets i195.9M137.9M171.3M209.6M98.7M
Liabilities
Current Liabilities
Accounts Payable i18.7K1.5M392.0K191.0K221.0K
Short-term Debt i7.2M1.6M3.9M6.3M2.4M
Current Portion of Long-term Debt-----
Other Current Liabilities10.9M8.8M10.0M14.8M7.0M
Total Current Liabilities i45.4M34.2M21.0M27.6M10.3M
Non-Current Liabilities
Long-term Debt i12.9M18.1M18.1M54.1M31.9M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i47.2M62.3M83.7M68.8M31.9M
Total Liabilities i92.6M96.5M104.6M96.4M42.2M
Equity
Common Stock i5.0M3.4M3.4M3.0M2.2M
Retained Earnings i-498.2M-400.8M-379.1M-317.8M-257.7M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i103.3M41.4M66.7M113.2M56.5M
Key Metrics
Total Debt i20.1M19.7M22.0M60.4M34.3M
Working Capital i134.0M86.8M133.5M163.9M69.7M

Balance Sheet Composition

ProQR Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-32.4M-27.7M-64.2M-60.8M-46.6M
Depreciation & Amortization i3.2M2.5M2.5M2.3M2.4M
Stock-Based Compensation i3.0M3.1M2.9M6.2M7.8M
Working Capital Changes i-15.5M0000
Operating Cash Flow i-45.2M-28.2M-57.1M-50.2M-41.0M
Investing Activities
Capital Expenditures i-1.7M-1.3M-702.0K-425.0K-924.0K
Acquisitions i-----
Investment Purchases i-19.8M----
Investment Sales i19.8M----
Investing Cash Flow i-4.8M-3.7M-702.0K-425.0K-924.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-0027.7M14.4M
Debt Repayment i-1.8M-2.6M-45.0M-820.0K-605.0K
Financing Cash Flow i81.7M-2.6M-30.9M135.3M13.8M
Free Cash Flow i-44.1M20.2M-69.2M-26.5M-48.0M
Net Change in Cash i31.8M-34.5M-88.7M84.6M-28.2M

Cash Flow Trend

ProQR Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.25
Forward P/E -4.79
Price to Book 3.54
Price to Sales 13.83
PEG Ratio -0.02

Profitability Ratios

Profit Margin -231.45%
Operating Margin -308.15%
Return on Equity -79.47%
Return on Assets -20.47%

Financial Health

Current Ratio 3.76
Debt to Equity 25.17
Beta 0.43

Per Share Data

EPS (TTM) $-0.47
Book Value per Share $0.64
Revenue per Share $0.18

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
prqr241.2M-7.253.54-79.47%-231.45%25.17
Vertex 102.8B27.775.8322.77%31.86%8.89
Regeneron 61.2B14.642.0215.34%31.37%9.04
Bright Minds 246.0M0.285.44-30.79%0.00%0.27
Atea Pharmaceuticals 244.9M-1.700.75-32.38%0.00%0.34
Third Harmonic Bio 242.8M12.460.89-19.94%0.00%1.10

Financial data is updated regularly. All figures are in the company's reporting currency.